Table 1 Performance indicators as predefined by clinical experts with the standard QI teams had to meet at the end of the study

After six months of treatment, 50% of the patients with severe anxiety disorders have a score of less than three on the Clinical Global Impression- Severity (CGI-S) scale.

Experienced quality of life, as measured by the Manchester Short Assessment of Quality of Life (MANSA) scale, improved by 15 points for 75% of patients with a dual diagnosis.

Social functioning, as measured by the Health of the Nation Outcome Scale (HONOS), improved by 2 points for 100% of patients with schizophrenia.

Monitoring:

At least 80% of the patients with anxiety disorders are monitored (every six weeks from the start of study and at least two times) using the Clinical Global Impression- Severity (CGI-S) scale.

The quality of life of 100% of the patients with a dual diagnosis is monitored (every 12 weeks and at least two times during the study) using the Manchester Short Assessment of Quality of Life (MANSA) scale.

The social functioning of 100% of the patients with schizophrenia is monitored at least two times using the Health of the Nation Outcome Scale (HONOS).

Screening/assessment:

Every month at least 4 out of 1000 patients suspected of anxiety disorders, are screened using the Four Dimensional Symptom Questionnaire (4DSQ).

Of all patients with dual diagnosis, 100% are screened for psychopathology with the Health of the Nation Outcome Scale (HONOS).